Jeffrey Anderson is a Cardiology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
701 University Blvd E
Suite 400
Tuscaloosa, AL 35401
Telephone
205-752-0694Registry record last updated 9 Oct 2007.
Clinical trials
- Assessment of Patients With suspeCted Coronary Artery Disease by Coronary calciUm fiRst strATegy vErsus Usual Care Approach.
Sponsor: Intermountain Health Care, Inc.
- Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease
Sponsor: Children's Hospital Medical Center, Cincinnati
- Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin
Sponsor: Intermountain Health Care, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year20257 payments
- Medtronic, Inc.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.4%Beta blocker21.7%Metoprolol Succinate51%Carvedilol31%Metoprolol Tartrate13%Atenolol4%Nebivolol Hcl1%Part D<11 patientsStatin8.6%Atorvastatin Calcium50%Rosuvastatin Calcium28%Simvastatin15%Pravastatin Sodium7%Part D<11 patients+ 17 more classes in this area
Blood & clotting
24.1%Factor Xa inhibitor12.8%Eliquis73%Xarelto27%Part D≥117 patientsP2Y12 inhibitor10.7%Clopidogrel72%Brilinta26%Prasugrel Hcl2%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
2.9%Potassium supplement2%Potassium Chloride100%Part D≥40 patientsProton pump inhibitor0.9%Pantoprazole Sodium71%Omeprazole29%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”